Back to top
more

MEDIFAST (MED)

(Delayed Data from NYSE)

$33.50 USD

33.50
323,644

-0.07 (-0.21%)

Updated Apr 25, 2024 04:00 PM ET

After-Market: $33.52 +0.02 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (92 out of 251)

Industry: Food - Miscellaneous

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Medifast's (MED) Transformation on Track Amid Macro Headwinds

by Zacks Equity Research

Medifast (MED) adapts to shifting consumer behavior to maintain its relevance. However, it is facing difficulties in attracting customers due to the rapidly changing economy and inflation.

MEDIFAST (MED) Down 11.5% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

MEDIFAST (MED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Medifast (MED) Soars 5.9%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Medifast (MED) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Innovations Aid Medifast (MED), Lower Customer Attraction Ails

by Zacks Equity Research

Medifast (MED) is foraying into medically supported weight management and sports nutrition segments. However, it continues to encounter difficulties in attracting customers.

Medifast (MED) Q4 Earnings Beat Estimates, Revenues Dip Y/Y

by Zacks Equity Research

Medifast's (MED) Q4 results reflect the impacts of poor customer acquisition. However, it is showing resilience, banking on its strategic focus on medically supported weight loss, indicating potential for growth.

Medifast (MED) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Medifast (MED) delivered earnings and revenue surprises of 10.10% and 9.80%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Medifast (MED) Q4 Earnings Coming Up: What Should You Know?

by Zacks Equity Research

Medifast's (MED) fourth-quarter results are likely to reflect the impacts of macroeconomic challenges like inflation, while key growth initiatives like innovation bode well.

Mondelez (MDLZ) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

Mondelez (MDLZ) delivered earnings and revenue surprises of 7.69% and 0.15%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Medifast's (MED) Holistic Health Solution, Innovation Bode Well

by Zacks Equity Research

Medifast's (MED) focus on combining lifestyle coaching with innovative health solutions and targeting diverse markets bode well amid challenges in customer acquisition and high costs.

Medifast (MED) Collaborates With LifeMD, Discontinues Dividend

by Zacks Equity Research

Medifast (MED) penetrates the medically supported weight loss market via a collaboration with LifeMD, Inc. (LFMD). The company discontinues quarterly cash dividends.

Here's How Much You'd Have If You Invested $1000 in Medifast a Decade Ago

by Zacks Equity Research

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

Why Is Medifast (MED) Down 1.1% Since Last Earnings Report?

by Zacks Equity Research

Medifast (MED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Medifast (MED) Poised on OPTAVIA ACTIVE Line Amid Cost Woes

by Zacks Equity Research

Medifast (MED) is proactively positioning itself to tap into the increasing demand for weight loss medications, showcasing a commitment to staying in touch with market trends.

Medifast (MED) Q3 Earnings Top Estimates, Revenues Decline Y/Y

by Zacks Equity Research

Medifast's (MED) Q3 results reflect challenges in customer acquisition. However, cost-reduction efforts and efficiency improvements as part of the "Fuel for the Future" plan bode well.

Medifast (MED) Queues for Q3 Earnings: What Awaits the Stock?

by Zacks Equity Research

Medifast's (MED) third-quarter results are likely to reflect concerns surrounding customer acquisition amid a challenging landscape. However, a focus on growth plans bodes well.

Sysco (SYY) Q1 Earnings Surpass Estimates

by Zacks Equity Research

Sysco (SYY) delivered earnings and revenue surprises of 4.90% and 0.38%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Medifast (MED) Poised on Expansion Initiatives Amid Cost Woes

by Zacks Equity Research

Medifast (MED) is making significant strides in its digital transformation efforts and expanding its OPTAVIA lifestyle solution to meet the increasing demand in the health and wellness market.

New Strong Sell Stocks for October 12th

by Zacks Equity Research

BGS, MS and MED have been added to the Zacks Rank #5 (Strong Sell) List on October 12, 2023.

Is First Trust SMID Cap Rising Dividend Achievers ETF (SDVY) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for SDVY

Medifast (MED) Gains on OPTAVIA Lifestyle Solution Strength

by Zacks Equity Research

Medifast's (MED) OPTAVIA program is a robust and adaptable solution focused on health and wellness. This holistic approach positions it for sustained long-term growth.

Why Is Medifast (MED) Down 7.4% Since Last Earnings Report?

by Zacks Equity Research

Medifast (MED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Should First Trust SMID Cap Rising Dividend Achievers ETF (SDVY) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for SDVY

Medifast's (MED) Q2 Earnings Top Estimates, Sales Decline Y/Y

by Zacks Equity Research

Medifast's (MED) second-quarter 2023 results reflect lower sales and earnings on reduced Coach productivity and cost inflation.

Medifast (MED) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Medifast (MED) delivered earnings and revenue surprises of 92.36% and 16.85%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

B&G Foods (BGS) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

B&G Foods (BGS) delivered earnings and revenue surprises of 66.67% and 1.87%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?